Back to News
Market Impact: 0.35
What United Therapeutics (UTHR) Said on Its Q3 Earnings Call
Source: marketbeat.com
Corporate EarningsHealthcare & BiotechCompany FundamentalsCorporate Guidance & OutlookProduct Launches
United Therapeutics reported record third-quarter 2026 revenue of $833 million, including record Tyvaso sales of $504 million. The company pushed back its planned regulatory submission for the soft mist inhaler to 2027, tempering the positive revenue news.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.10
Ticker Sentiment
UTHR0.55
More News
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Voters rebuff data centers in every ballot measure except one during the 2026 midterms
- Asian chip stocks slide as disappointing Qualcomm, Arm earnings weigh
- Snap shares fall over 10% on third-quarter earnings miss
- ‘Seismic’ blue wave triggers the sinking of oil prices, energy stocks, and the chances of power permitting reform
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT